## medix infusion

## Skyrizi IV Order Form



(risankizumab-rzaa) PATIENT INFORMATION \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_ Wt: \_\_\_\_ Ibs kg Patient Name: \_\_\_\_\_ Primary Language: \_\_\_\_\_\_ Allergies: \_\_\_\_\_ Patient Preferred Location: \_\_\_\_ **DIAGNOSIS & CLINICAL INFORMATION** <ICD 10 CODE REQUIRED> ICD 10 Code K50.0 \_\_\_\_\_ Crohn's Disease, Small Intestine K50.1 \_\_\_\_\_ Crohn's Disease, Large Intestine K50.8 \_\_\_\_\_ Crohn's Disease, Small and Large Intestine K50.9 \_\_\_\_\_ Crohn's Disease, Unspecified REQUIRED: Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. LAB RESULTS: Include Negative TB within 12 months. PRESCRIPTION SKYRIZI IV (risankizumab-rzaa) Lab Orders+ Required: Negative TB, Liver enzymes and bilirubin at weeks 0 and 4 Loading Dose IV Infuse 600 mg in 250 ml of 5% Dextrose over at least 1 hour at +Medix Infusion will draw maintenance labs unless otherwise weeks 0, 4, and 8 directed by Referring Provider Post Treatment Observations: The patient is observed for 30 minutes following the first administration. Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol. Comments: PRESCRIBER INFORMATION Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_\_ NPI #: \_\_\_\_\_\_ Specialty: \_\_\_\_\_ Supervising Physician: \_\_\_\_\_ (If Applicable) Address: \_\_\_\_\_\_ City: \_\_\_\_\_\_ State: \_\_\_\_\_ Zip:\_\_\_\_\_ Contact Name: \_\_\_\_\_\_ Email: \_\_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_